APA (7th ed.) Citation

Kim, S., Peters, J., Lang, M. G., Lee, J., Cha, J., & Kim, Y. (2026). Safety and Effectiveness of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. Infection & Chemotherapy, 58(1), 122. https://doi.org/10.3947/ic.2025.0140

Chicago Style (17th ed.) Citation

Kim, Shin-Woo, Jami Peters, Markus G. Lang, Jeong-a Lee, Jinhye Cha, and Yeon-Sook Kim. "Safety and Effectiveness of Biktarvy® (bictegravir/emtricitabine/tenofovir Alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea." Infection & Chemotherapy 58, no. 1 (2026): 122. https://doi.org/10.3947/ic.2025.0140.

MLA (9th ed.) Citation

Kim, Shin-Woo, et al. "Safety and Effectiveness of Biktarvy® (bictegravir/emtricitabine/tenofovir Alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea." Infection & Chemotherapy, vol. 58, no. 1, 2026, p. 122, https://doi.org/10.3947/ic.2025.0140.